. . . . . . . . . "malaria hydroxychloroquine sulfate tablets are indicated for the treatment of uncomplicated malaria due to p falciparum p malariae p ovale p vivax hydroxychloroquine sulfate tablets are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported limitations of use in malaria hydroxychloroquine sulfate tablets are not recommended for the treatment of complicated malaria hydroxychloroquine sulfate tablets are not effective against chloroquine or hydroxychloroquine resistant strains of plasmodium clinical pharmacology microbiology plasmodium hydroxychloroquine sulfate tablets are not recommended for malaria prophylaxis in geographic areas where chloroquine resistance occurs hydroxychloroquine sulfate tablets do not prevent relapses of p vivax p ovale p vivax p ovale clinical pharmacology microbiology prior to prescribing hydroxychloroquine sulfate tablets for the treatment or prophylaxis of malaria consult the centers for disease control and prevention cdc malaria website http www cdc gov malaria lupus erythematosus hydroxychloroquine sulfate tablets are indicated for the treatment of chronic discoid lupus erythematosus and systemic lupus erythematosus in adults rheumatoid arthritis hydroxychloroquine sulfate tablets are indicated for the treatment of acute and chronic rheumatoid arthritis in adults" . . . . . . "RSA" . "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB" . "co5nkSVsbhNLqGDvAqEb0SYKaqorWrt5qvHS58xQ+W82Cr+slLAU1ynuvceE/TacPT1qEn+mJQfd38IQjA7b7HgTF8w0sDHjgd4IBRJPbNZH6F8ERhewSd+W3py6Uo9pkr4ldgcGQD5+guRxjZ0Jx1364r51klEYiKx2v/rbHW4=" . . "2021-06-15T18:42:22.763+02:00"^^ . . . . .